Cargando…

Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21

Children with Down syndrome (DS) have a high risk for acute myeloid leukemia (DS-ML). Genomic characterization of DS-ML blasts showed the presence of unique mutations in GATA1, an essential hematopoietic transcription factor, leading to the production of a truncated from of GATA1 (GATA1s). GATA1s, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Barwe, Sonali P., Sebastian, Aimy, Sidhu, Ishnoor, Kolb, Edward Anders, Gopalakrishnapillai, Anilkumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870267/
https://www.ncbi.nlm.nih.gov/pubmed/35203280
http://dx.doi.org/10.3390/cells11040628
_version_ 1784656701428858880
author Barwe, Sonali P.
Sebastian, Aimy
Sidhu, Ishnoor
Kolb, Edward Anders
Gopalakrishnapillai, Anilkumar
author_facet Barwe, Sonali P.
Sebastian, Aimy
Sidhu, Ishnoor
Kolb, Edward Anders
Gopalakrishnapillai, Anilkumar
author_sort Barwe, Sonali P.
collection PubMed
description Children with Down syndrome (DS) have a high risk for acute myeloid leukemia (DS-ML). Genomic characterization of DS-ML blasts showed the presence of unique mutations in GATA1, an essential hematopoietic transcription factor, leading to the production of a truncated from of GATA1 (GATA1s). GATA1s, together with trisomy 21, is sufficient to develop a pre-leukemic condition called transient abnormal myelopoiesis (TAM). Approximately 30% of these cases progress into DS-ML by acquisition of additional somatic mutations in a stepwise manner. We previously developed a model for TAM by introducing disease-specific GATA1 mutation in trisomy 21-induced pluripotent stem cells (iPSCs), leading to the production of N-terminally truncated short form of GATA1 (GATA1s). In this model, we used CRISPR/Cas9 to introduce a co-operating mutation in STAG2, a member of the cohesin complex recurrently mutated in DS-ML but not in TAM. Hematopoietic differentiation of GATA1 STAG2 double-mutant iPSC lines confirmed GATA1s expression and the loss of functional STAG2 protein, leading to enhanced production of immature megakaryocytic population compared to GATA1 mutant alone. Megakaryocyte-specific lineage expansion of the double-mutant HSPCs exhibited close resemblance to the DS-ML immunophenotype. Transcriptome analysis showed that GATA1 mutation resulted in downregulation of megakaryocytic and erythrocytic differentiation pathways and interferon α/β signaling, along with an upregulation of pathways promoting myeloid differentiation such as toll-like receptor cascade. The co-occurrence of STAG2 knockout partially reverted the expression of genes involved in myeloid differentiation, likely leading to enhanced self-renewal and promoting leukemogenesis. In conclusion, we developed a DS-ML model via hematopoietic differentiation of gene-targeted iPSCs bearing trisomy 21.
format Online
Article
Text
id pubmed-8870267
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88702672022-02-25 Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21 Barwe, Sonali P. Sebastian, Aimy Sidhu, Ishnoor Kolb, Edward Anders Gopalakrishnapillai, Anilkumar Cells Article Children with Down syndrome (DS) have a high risk for acute myeloid leukemia (DS-ML). Genomic characterization of DS-ML blasts showed the presence of unique mutations in GATA1, an essential hematopoietic transcription factor, leading to the production of a truncated from of GATA1 (GATA1s). GATA1s, together with trisomy 21, is sufficient to develop a pre-leukemic condition called transient abnormal myelopoiesis (TAM). Approximately 30% of these cases progress into DS-ML by acquisition of additional somatic mutations in a stepwise manner. We previously developed a model for TAM by introducing disease-specific GATA1 mutation in trisomy 21-induced pluripotent stem cells (iPSCs), leading to the production of N-terminally truncated short form of GATA1 (GATA1s). In this model, we used CRISPR/Cas9 to introduce a co-operating mutation in STAG2, a member of the cohesin complex recurrently mutated in DS-ML but not in TAM. Hematopoietic differentiation of GATA1 STAG2 double-mutant iPSC lines confirmed GATA1s expression and the loss of functional STAG2 protein, leading to enhanced production of immature megakaryocytic population compared to GATA1 mutant alone. Megakaryocyte-specific lineage expansion of the double-mutant HSPCs exhibited close resemblance to the DS-ML immunophenotype. Transcriptome analysis showed that GATA1 mutation resulted in downregulation of megakaryocytic and erythrocytic differentiation pathways and interferon α/β signaling, along with an upregulation of pathways promoting myeloid differentiation such as toll-like receptor cascade. The co-occurrence of STAG2 knockout partially reverted the expression of genes involved in myeloid differentiation, likely leading to enhanced self-renewal and promoting leukemogenesis. In conclusion, we developed a DS-ML model via hematopoietic differentiation of gene-targeted iPSCs bearing trisomy 21. MDPI 2022-02-11 /pmc/articles/PMC8870267/ /pubmed/35203280 http://dx.doi.org/10.3390/cells11040628 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Barwe, Sonali P.
Sebastian, Aimy
Sidhu, Ishnoor
Kolb, Edward Anders
Gopalakrishnapillai, Anilkumar
Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21
title Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21
title_full Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21
title_fullStr Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21
title_full_unstemmed Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21
title_short Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21
title_sort modeling down syndrome myeloid leukemia by sequential introduction of gata1 and stag2 mutations in induced pluripotent stem cells with trisomy 21
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870267/
https://www.ncbi.nlm.nih.gov/pubmed/35203280
http://dx.doi.org/10.3390/cells11040628
work_keys_str_mv AT barwesonalip modelingdownsyndromemyeloidleukemiabysequentialintroductionofgata1andstag2mutationsininducedpluripotentstemcellswithtrisomy21
AT sebastianaimy modelingdownsyndromemyeloidleukemiabysequentialintroductionofgata1andstag2mutationsininducedpluripotentstemcellswithtrisomy21
AT sidhuishnoor modelingdownsyndromemyeloidleukemiabysequentialintroductionofgata1andstag2mutationsininducedpluripotentstemcellswithtrisomy21
AT kolbedwardanders modelingdownsyndromemyeloidleukemiabysequentialintroductionofgata1andstag2mutationsininducedpluripotentstemcellswithtrisomy21
AT gopalakrishnapillaianilkumar modelingdownsyndromemyeloidleukemiabysequentialintroductionofgata1andstag2mutationsininducedpluripotentstemcellswithtrisomy21